Indo-MIM
FinMinutes Deep Business Model & Edge
INDO-MIM Limited provides end-to-end solutions for manufacturing precision engineering components using metal injection molding (MIM), investment casting, and precision machining technologies. The company earns revenue primarily through the direct sale of these precision components to original equipment manufacturers (OEMs) across the automotive, defence, medical, aerospace, and consumer product sectors.
What this company actually does — full breakdown ▾
INDO-MIM Limited is globally the largest manufacturer of precision engineering components using Metal Injection Molding (MIM) technology, commanding a 6.8% global market share. The company operates a backward-integrated, dual-shore manufacturing model with 15 facilities spread across India, the United States, the United Kingdom, and Mexico. This scale allows it to serve a highly diversified customer base of over 730 active customers worldwide, heavily mitigating concentration risk. In Fiscal 2026, exports formed 77.20% of its revenue from operations. The company's products—ranging from turbocharger vanes to surgical laparoscopy jaws and assault rifle components—cater to the Automotive (24.61%), Defence (18.69%), Medical (18.08%), Aerospace (11.96%), and Consumer Products (10.80%) sectors. A key operational vulnerability is its supply chain dependence; it imports roughly 61% of its raw materials, and in Fiscal 2026, its top 10 suppliers accounted for 95.24% of its material purchases. The company's unique edge stems from its massive installed capacity, dedicated in-house tooling operations capable of rapidly developing new molds, and successful integration of adjacent technologies like vacuum casting.
- Sale of products — Revenue derived from the manufacture and supply of precision engineered components.
- Tooling income — Income from development and engineering services under negotiated contract agreements with customers.
- Sale of services — Revenue generated from associated engineering and component processing services.
Global market leadership (6.8% share) in Metal Injection Molding with immense installed capacity, extensive backward integration in mold design and tooling, and high entry barriers due to significant capital and technological expertise requirements.
The Offer
Follow the Money — Use of Proceeds
- Repayment/ prepayment, in full or part, of all or certain outstanding borrowings availed by our Company — ₹400.00 cr
- General corporate purposes
Valuation at the Offer Price
The filing does not print a single headline multiple, so this one is ours: the upper band divided by the latest restated earnings per share — the same arithmetic the “Basis for the Offer Price” section performs. It is struck on pre-issue earnings; where the issue creates new shares, the post-issue multiple is computed in the workings below. The peer group is the one the filing itself names. A premium is not the same thing as expensive and a discount is not the same thing as cheap — the peer table and the reasons sit further down this page.
FinMinutes IPO Score — How It's Built
Transparent, deterministic, computed from the filing — not an opinion. Open any component below to see exactly what it measures and what it is worth. Components with no disclosed input are dropped from the weighting entirely rather than held at an invented neutral, because a constant inside a weighted average is not neutral — it quietly drags every score toward the middle. Weighted across 5 live components.
88% of the designed weighting had real data behind it on this issue. Not yet scored here: Anchor Quality. A lower coverage figure does not mean a worse company — it means we are standing behind less of the picture, and you should read the findings below rather than the headline number.
How this is measured12%
Whether fresh capital actually enters the business. A predominantly offer-for-sale issue is marked down ONLY when the financials are weak. A profitable, cash-rich company selling down is treated as neutral, not penalised, because it does not need the money.
How this is measured32%
Driven by the models battery run on the filing's own restated numbers: the Piotroski fundamental tests (scored out of those we could actually run), the Altman Z-double-prime solvency zone, and the direction of profit across the disclosed period. It is not a single yes/no on last year's profit.
How this is measured10%
The post-issue earnings multiple against the peer median disclosed in the filing. A discount to the median scores well and a premium scores badly. When the filing does not disclose comparable peer multiples, this component is dropped from the weighting rather than held at a made-up neutral.
How this is measured6%
A proxy for syndicate strength, based today only on how many lead managers are on the issue: 75 where three or more banks are involved, 60 otherwise. We have not built a bank-by-bank track record, so treat this as a rough signal. When the filing does not disclose the syndicate, this component is dropped from the weighting rather than guessed.
How this is measured28%
Starts at 100 and loses points for every material finding: 12 for a flagged finding, 4 for a noted one. Two kinds feed it. DERIVED findings are computed from the filed numbers against stated thresholds — operating cash negative while profit is positive, related-party revenue above 15% of total, revenue rising while profit falls, goodwill above 30% of net worth, receivables growing more than 1.3x faster than sales, cash below half of short-term debt. Those are reproducible: the same filing gives the same answer every time, and the rule is printed beside the finding. READ findings come from the forensic sweep of the notes. Contingent liabilities, related-party intensity, customer concentration, litigation, auditor qualifications, statutory dues, promoter funding. Findings that record the ABSENCE of a problem — no litigation pending, an unmodified audit opinion — deduct nothing. This is the component our forensic read drives directly, and it moves most between companies.
3-Year Financial & Growth Trend
| Metric | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue (₹ Cr) | 4192.985 | 3329.577 | 2870.395 |
| Net Profit (₹ Cr) | 533.543 | 423.734 | 283.734 |
| PAT Margin | 12.72% | 12.73% | 9.88% |
Revenue Breakdown
- Automotive Products Group (APG): 24.61%
- Defence Products Group (DPG): 18.69%
- Medical Products Group (MPG): 18.08%
- Aerospace: 11.96%
- Consumer Products Group (CPG): 10.8%
- Others: 15.86%
Market Context
NOT part of the FinMinutes ScoreThe Score above is what the filing says. Everything in this box is what the crowd says. We keep them apart on purpose — every other site blends the two and calls the result a rating. Demand is real information, but it is information about the market, not about the company, and it changes by the hour while the company does not.
The market is bidding this issue enthusiastically. The headline financials look strong, but our forensic read of the filing is not clean — the risk band is high and the footnotes carry material flags. That gap is the fact worth noticing. Strong demand is information about the market; the flags are information about the company, and the two are not saying the same thing here. Read the Forensic Findings below before the momentum decides it for you.
Subscription is low early in a book and high at the end, because most bids arrive in the final hours. A number read on day one says more about the clock than the company — which is precisely why it is not in the Score. GMP is unofficial, unregulated, and easily moved. Neither is a recommendation.
Applying, and Who Handles the Allotment
Check allotment status on the registrar’s own portal → We link the registrar directly rather than mirroring the form.
Deep Financials
Revenue, EBITDA and profit are what every listing site prints. Below are the full restated statements as disclosed, the ratios we compute from them, and a DuPont decomposition of the return on equity. A prospectus carries three years, not ten — that is the document’s ceiling, and within it we go as deep as it allows.
Income StatementThe profit and loss as filed, then what we derive from it — kept apart.
Statutory order, exactly as restated in the filing. Finance cost and depreciation sit inside Total Expenses under Ind AS, which is why they are listed among the expense lines here rather than below the total. The expense rows sum to the total. Rows the filing does not disclose separately are omitted rather than left blank.
| Income Statement — as filed (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Revenue from Operations | 4,192.99 | 3,329.58 | 2,870.40 |
| Other Income | 127.72 | 44.40 | 29.99 |
| Total Income | 4,320.70 | 3,373.97 | 2,900.38 |
| Cost of Materials Consumed | 874.88 | 583.43 | 450.17 |
| Employee Benefit Expense | 899.06 | 697.07 | 648.41 |
| Finance Cost | 166.80 | 96.10 | 87.41 |
| Depreciation & Amortisation | 220.06 | 198.81 | 174.36 |
| Other Expenses | 1,346.40 | 1,222.11 | 1,063.57 |
| Total Expenses | 3,508.93 | 2,691.89 | 2,388.70 |
| Profit Before Tax | 733.74 | 581.00 | 435.21 |
| Tax Expense | 200.20 | 157.27 | 151.47 |
| Profit After Tax | 533.54 | 423.73 | 283.73 |
| EPS - Basic | 11.06 | 8.79 | 5.89 |
| EPS - Diluted | 10.87 | 8.60 | 5.89 |
Balance SheetWhat the company owns, owes, and is worth on paper.
| Balance Sheet (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Share Capital | 48.42 | 48.20 | 48.20 |
| Reserves & Surplus | 2,771.14 | 2,151.23 | 2,002.31 |
| Net Worth | 2,819.55 | 2,199.43 | 2,050.51 |
| Long-term Borrowings | 528.94 | 522.09 | 587.61 |
| Short-term Borrowings | 561.55 | 725.11 | 497.41 |
| Total Borrowings | 1,090.49 | 1,247.20 | 1,085.01 |
| Trade Payables | 199.86 | 224.37 | 200.55 |
| Current Liabilities | 1,182.41 | 1,238.66 | 893.64 |
| Total Liabilities | 2,077.78 | 1,941.41 | 1,707.00 |
| Property, Plant & Equipment | 1,824.43 | 1,512.33 | 1,434.15 |
| Capital Work in Progress | 131.71 | 169.79 | 146.95 |
| Intangible Assets | 1.82 | 1.90 | 2.28 |
| Investments | 9.88 | 12.97 | 10.55 |
| Inventories | 894.99 | 899.16 | 676.89 |
| Trade Receivables | 763.79 | 643.82 | 554.24 |
| Cash & Equivalents | 389.56 | 174.62 | 232.86 |
| Current Assets | 2,471.92 | 2,127.49 | 1,827.43 |
| Total Assets | 4,897.33 | 4,140.84 | 3,757.51 |
Cash FlowWhere the cash actually went. Often the most honest statement of the three.
| Cash Flow (₹ Cr) | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Cash from Operating Activities | 1,077.24 | 506.27 | 458.33 |
| Capital Expenditure | 417.27 | 376.21 | 376.05 |
| Net Cash from Investing Activities | -536.55 | -335.93 | -475.51 |
| Net Cash from Financing Activities | -356.08 | -237.94 | -92.68 |
| Net Change in Cash | 214.94 | -58.24 | -98.60 |
Ratio AnalysisProfitability, leverage, liquidity, efficiency and earnings quality — computed by us.
Every ratio below is computed by us from the line items the company disclosed — not copied from anywhere. The arithmetic is standard; the point is that somebody actually did it. Blank cells mean the filing did not disclose the inputs, and we would rather show a gap than invent a number.
| Ratio | FY26 | FY25 | FY24 |
|---|---|---|---|
| Profitability | |||
| EBITDA Margin (%) | 25.9 | 26 | 24 |
| EBIT Margin (%) | 20.8 | 20.1 | 18 |
| PAT Margin (%) | 12.7 | 12.7 | 9.9 |
| Return on Equity (%) | 18.9 | 19.3 | 13.8 |
| Return on Capital Employed (%) | 23 | 19.6 | 16.7 |
| Return on Assets (%) | 10.9 | 10.2 | 7.6 |
| Leverage | |||
| Debt / Equity (x) | 0.39 | 0.57 | 0.53 |
| Net Debt / EBITDA (x) | 0.63 | 1.22 | 1.22 |
| Interest Coverage (x) | 5.4 | 7.05 | 5.98 |
| Liquidity | |||
| Current Ratio (x) | 2.09 | 1.72 | 2.04 |
| Quick Ratio (x) | 1.33 | 0.99 | 1.29 |
| Efficiency | |||
| Asset Turnover (x) | 0.86 | 0.8 | 0.76 |
| Receivable Days | 66 | 71 | 70 |
| Inventory Days | 373 | 563 | 549 |
| Payable Days | 83 | 140 | 163 |
| Cash Conversion Cycle (days) | 356 | 494 | 456 |
| Quality of Earnings | |||
| Operating Cash Flow / PAT (x) | 2.02 | 1.19 | 1.62 |
| Accruals Ratio (%) | -11.1 | -2 | -4.6 |
| Capex / Depreciation (x) | 1.9 | 1.89 | 2.16 |
| Inventory and payable days are measured against cost of goods (materials consumed + purchases of stock-in-trade + change in inventories). Receivable days against revenue. | |||
DuPont DecompositionWhy the return on equity is what it is: margin, efficiency, or leverage.
A headline return on equity tells you what. The DuPont decomposition tells you why — whether the return is earned through margin, through asset efficiency, or simply through leverage. Two companies can post an identical ROE for opposite reasons, and only one of them is safe.
| Component | FY26 | FY25 | FY24 |
|---|---|---|---|
| Net Margin (PAT / Revenue) | 12.7% | 12.7% | 9.9% |
| Asset Turnover (Revenue / Assets) | 0.86x | 0.8x | 0.76x |
| Equity Multiplier (Assets / Net Worth) | 1.74x | 1.88x | 1.83x |
| = Return on Equity | 18.9% | 19.3% | 13.8% |
| Tax Burden (PAT / PBT) | 0.73x | 0.73x | 0.65x |
| Interest Burden (PBT / EBIT) | 0.81x | 0.86x | 0.83x |
| Operating Margin (EBIT / Revenue) | 21.5% | 20.3% | 18.2% |
Computed from the disclosed statements. Where the filing omits an input, the row is left blank rather than estimated.
Quality of EarningsWhat the statements say when you read them against each other.
What the statements say once you read them against each other. These are observations, not verdicts — every one is arithmetic on the numbers the company itself disclosed, and each is stated so you can go and check it in the filing.
- Operating cash flow was 2.02x reported profit in FY26. Earnings are converting into cash, which is what you want to see and frequently is not the case.
Forensic ModelsBeneish, Altman, Piotroski and the Montier C-score — plus our own final-year check.
Beneish M-Score
M = -2.71An eight-variable model built to detect earnings manipulation, and built to run on exactly two consecutive years — which is what a prospectus gives us. It belongs here more than anywhere: a company about to list has the maximum possible incentive to have dressed up the very years it is about to show you. A score above −1.78 is the threshold at which the model says the accounts merit a closer look. It is a screening signal, not an accusation, and it was calibrated on listed companies elsewhere. Read the eight components, not just the total.
| Component | Value | What it captures |
|---|---|---|
| DSRI Days Sales in Receivables Index (Receivables_t / Sales_t) / (Receivables_t-1 / Sales_t-1) | 0.942 | Above 1 means receivables grew faster than sales. Revenue may be being recognised ahead of collection. |
| GMI Gross Margin Index GrossMargin_t-1 / GrossMargin_t | 1.042 | Above 1 means margins deteriorated. A firm with worsening prospects has more incentive to manipulate. |
| AQI Asset Quality Index AQ_t / AQ_t-1, where AQ = 1 - (CurrentAssets + PPE) / TotalAssets | 1.014 | Above 1 means a rising share of assets is soft (neither current nor fixed) — capitalised costs can hide here. |
| SGI Sales Growth Index Sales_t / Sales_t-1 | 1.259 | Growth is not manipulation. But high-growth firms face more pressure to keep the streak going. |
| DEPI Depreciation Index DepRate_t-1 / DepRate_t, where DepRate = Dep / (Dep + PPE) | 1.079 | Above 1 means assets are being depreciated more slowly — a quiet way to lift reported profit. |
| SGAI SG&A Index (SGA_t / Sales_t) / (SGA_t-1 / Sales_t-1), SGA proxied as employee cost + other expenses | 0.929 | A proxy, because filings rarely break out SG&A cleanly. Read it as a direction, not a precise figure. |
| LVGI Leverage Index Leverage_t / Leverage_t-1, where Leverage = (CurrentLiab + LongTermDebt) / TotalAssets | 0.822 | Above 1 means leverage rose. Debt covenants create pressure to hit numbers. |
| TATA Total Accruals to Total Assets (PAT - CashFromOperations) / TotalAssets | -0.111 | The gap between reported profit and cash generated. The single heaviest term in the model — and the one that catches profit that never became cash. |
M = -2.71, below the −1.78 threshold. The model does not flag these accounts.
Altman Z″-Score (emerging markets)
Z″ = 9.48 · SafeA distress-prediction model. We use the Z″ variant deliberately: the original Z was calibrated on American manufacturers and misleads badly on Indian services companies. Above 2.6 is the safe zone, 1.1 to 2.6 is grey, below 1.1 is the distress zone. Like every model of its kind it is a screen, not a prophecy.
| X1 — Working Capital / Total Assets | 0.263 |
| X2 — Reserves / Total Assets | 0.566 |
| X3 — EBIT / Total Assets | 0.184 |
| X4 — Net Worth / Total Liabilities | 1.357 |
| Z″ = 3.25 + 6.56·X1 + 3.26·X2 + 6.72·X3 + 1.05·X4 | 9.48 |
X2 is meant to read retained earnings. The filing reports Other Equity, which also holds securities premium paid in by investors, so X2 here runs on reserves and reads higher than true retained earnings would. The more premium the company has raised before listing, the more Z″ is flattered.
Piotroski F-Score (adapted)
7 / 8Nine yes-or-no tests of fundamental strength — except we run eight. One of the original nine asks whether the company issued new shares, which is plainly absurd to ask of a company whose entire purpose at this moment is to issue shares. We drop that test, and we would rather tell you that than quietly fudge it.
- ✓Positive return on assets
- ✓Positive operating cash flow
- ✓Return on assets improving
- ✓Cash flow exceeds profit (quality of earnings)
- ✓Long-term leverage decreasing
- ✓Current ratio improving
- ✗Gross margin improving
- ✓Asset turnover improving
Montier C-Score
2 of 6 signsSix yes-or-no signs that reported profit may be running ahead of the business, from James Montier’s 2008 screen, read here for FY26 against FY25. Each is a direction in the statements, not a judgement. Several together are a reason to read the accounting policies and notes closely; none on its own means anything is wrong, and growing companies trip some of them honestly.
- ○Gap between profit and operating cash flow widening · PAT − CFO: ₹-82.5 cr in FY25, ₹-543.7 cr in FY26
- ○Receivable days rising · 71 days in FY25, 66 days in FY26
- ○Inventory days rising · 563 days in FY25, 373 days in FY26 (on cost of goods)
- ○Other current assets rising against revenue · 12.3% of revenue in FY25, 10.1% in FY26 (current assets less cash, receivables and inventory)
- ●Depreciation falling against fixed assets · 13.1% of net block in FY25, 12.1% in FY26
- ●Total assets growing more than 10% a year · 18.3% in FY26
Ratios Nobody Prints
- Contingent liabilities / Net worth: 8.1%
Contingent liabilities of 227.45 cr against a net worth of 2,819.55 cr — 8.1% of what the company is worth on paper. These are obligations that sit off the balance sheet but could land on it. What they consist of matters as much as the size: a corporate guarantee to a subsidiary is a different animal from a disputed tax demand, and the filing says which. - Related-party revenue / Total revenue: 1.1%
1.1% of revenue in FY26 came from entities connected to the promoters. Revenue you sell to yourself is not the same as revenue you won in the market. - Cash / Short-term borrowings: 0.69x
Short-term borrowings of 561.55 cr against cash of 389.56 cr. Debt that must be refinanced within a year is only comfortable while lenders stay comfortable. - Promoter remuneration / PAT: 17.8%
Managerial remuneration to the promoter group was 95.01 cr against a profit of 533.54 cr. This is a legitimate cost — but it is also a route by which value leaves a company before it ever reaches a minority shareholder.
What the Price RequiresThe profit the offer price needs, at three hurdle rates. A restatement of the price, not a view on it.
At the upper band of ₹485.00, the market value is ₹23,806 cr. A buyer who wants a given return each year from a business that never grows needs annual profit of market value × that return. The three rates are round hurdle rates, not this company’s cost of capital, so pick the one that is yours. The years columns assume profit compounds from the FY26 figure and the price stands still. None of this is a forecast, a fair value or a target.
| Hurdle rate | Profit the price needs | × FY26 profit | Years at 15% growth | Years at 25% growth |
|---|---|---|---|---|
| 10% a year | ₹2,381 cr | 4.5x | 10.7 | 6.7 |
| 12% a year | ₹2,857 cr | 5.4x | 12.0 | 7.5 |
| 14% a year | ₹3,333 cr | 6.2x | 13.1 | 8.2 |
- Earnings yield at the upper band: 2.24% (FY26 profit ÷ market value).
- Free cash flow yield: 2.77% (operating cash flow less capital expenditure, ₹660 cr, ÷ market value).
The Formula NotebookEvery number above, with the working shown. Check us.
Every number we publish, with the working shown. The formula, the same formula with this company’s actual figures put into it, the answer, and what it is for. Check us. That is the point.
PAT ÷ Net Worth533.54 ÷ 2,819.55What the company earned on the money shareholders have in it. The headline measure of return — and the one the DuPont section takes apart.
EBIT ÷ (Net Worth + Total Borrowings)900.54 ÷ (2,819.55 + 1,090.49) = 900.54 ÷ 3,910.04Return on ALL the capital in the business, borrowed as well as owned. Unlike ROE, it cannot be flattered by taking on debt.
EBITDA ÷ Revenue1,120.60 ÷ 4,192.99Operating profitability before the effects of debt, tax and depreciation. What the business earns from the act of trading.
Total Borrowings ÷ Net Worth1,090.49 ÷ 2,819.55How much the company has borrowed against what it owns. High is not automatically bad — ask whether the borrowing is being serviced comfortably.
EBIT ÷ Finance Cost900.54 ÷ 166.80How many times over operating profit covers the interest bill. Below about 2x, a meaningful share of what the business earns is going to lenders rather than owners.
(Trade Receivables ÷ Revenue) × 365(763.79 ÷ 4,192.99) × 365How long the company waits to be paid. Rising receivable days mean revenue is being booked faster than it is collected — which is where a great many accounting problems begin.
Inventory Days + Receivable Days − Payable Days373 + 66 − 83How long cash is tied up in the operating cycle before it comes back. The longer it is, the more working capital the business must fund.
Cash from Operations ÷ PAT1,077.24 ÷ 533.54Did the profit turn into cash? Profit is an opinion; cash is a fact. When this sits well below 1x for long, the two are drifting apart, and the filing is where you find out why.
(PAT − Cash from Operations) ÷ Total Assets(533.54 − 1,077.24) ÷ 4,897.33 = -543.70 ÷ 4,897.33The share of reported profit that exists on paper rather than in the bank. It is also the heaviest single term in the Beneish model, for good reason.
Price × Post-issue Shares₹485.00 × 490,839,926 sharesWhat the whole company is being valued at, if the issue prices at the top of the band.
Market Cap + Total Borrowings − Cash23,805.74 + 1,090.49 − 389.56What it would actually cost to buy the whole business: you take on its debt and you get its cash. This is the number a buyer cares about, and it is the reason a P/E on its own can mislead.
Enterprise Value ÷ EBITDA24,506.66 ÷ 1,120.60The multiple that includes debt. Two companies on the same P/E — one debt-free, one heavily borrowed — are not the same investment, and only this number tells you so.
Market Cap ÷ PAT23,805.74 ÷ 533.54The familiar multiple. Useful, but blind to debt — read it alongside EV/EBITDA, never instead of it.
EBIT × (1 − tax rate) ÷ (Net Worth + Debt − Cash)NOPAT ÷ Invested CapitalWhat the business earns on the capital actually at work in it. We do not compare this to a cost of capital: that would need a beta, an unlisted company has none, and inventing one would be theatre.
Latest full-year PAT ÷ market value₹533.54 cr ÷ ₹23,805.74 crThe P/E turned upside down: what each rupee of market value earns today. Set it against what you could earn elsewhere; the gap is what growth has to make up.
(Operating cash flow − capital expenditure) ÷ market value₹659.98 cr ÷ ₹23,805.74 crCash left after the company pays for its own investment, against the price of the whole company. Profit can be shaped by accounting choices; this is harder to shape.
P/E ÷ trailing PAT growth (%)44.62 ÷ 25.9%PEG was designed for FORWARD growth. This one uses TRAILING growth, because that is all a prospectus gives us — and the final year before an IPO is very often the best year the company will have for a while. A low PEG here may say more about the timing of the filing than about the price. We show it because it was asked for; we show the growth denominator beside it so it cannot mislead you quietly.
Workspace
The post-issue share count is stated as “[•]” in this filing until final pricing, so we derive it: profit after tax divided by earnings per share gives the pre-issue count, and the fresh issue divided by the offer price gives the new shares. Everything below rests on that derivation. It is close, not exact.
The numbers are already loaded. Move the offer price and watch every multiple move with it. Set your own growth and margin and see what they imply two years out. These are your assumptions, not our forecast — we have no view on what this company will earn, and the moment we published one we would be doing something we are not registered to do. What we can do is put the arithmetic in front of you and get out of the way.
Price defaults to the top of the band. Margin defaults to what the company actually reported in FY26.
Projections are arithmetic on the inputs you typed. They are not a forecast, not a recommendation, and not a view on whether this offer is worth taking. Educational only.
Institutional Alpha: DRHP Deep Dive
The global Metal Injection Molding (MIM) industry provides a competitive alternative to traditional stamped or machined parts by offering immense design flexibility, enabling the mass production of highly complex, small-geometry components with superior strength and corrosion resistance. The market is primarily driven by rising demand from the medical devices, aerospace, automotive, and consumer electronics sectors. The industry presents substantial entry barriers due to the need for high capital investments in specialized equipment, lengthy OEM qualification timelines, and the necessity of deep metallurgical and polymer science expertise. Key challenges include high tooling costs, volatile feedstock prices, and technological competition from precision CNC machining and metal additive manufacturing.
Future Planning & Capital Allocation
The IPO includes a ₹5,000 million Fresh Issue, of which ₹4,000 million is earmarked specifically to repay or prepay existing borrowings. This aggressive deleveraging will reduce interest outflows (which stood at ₹1,668 million in FY26) and improve net margins, while the OFS provides a partial exit for the Corporate Promoter.
Source: RHP p. 101-102, 721Competitive Position
INDO-MIM boasts a near-unassailable moat in the precision MIM market due to massive capital requirements and long OEM qualification cycles. Its 6.8% global market share and deeply entrenched relationships in high-compliance industries (aerospace, defence, medical) give it strong pricing power and recurring revenue visibility.
Source: RHP p. 192, 411-412Execution / Track Record
Operationally, the company has scaled impressively, expanding revenues from ₹28,703 million in FY24 to ₹41,929 million in FY26 while maintaining robust EBITDA margins above 25%. However, capital allocation via acquisitions has been highly value-destructive, with massive consecutive impairments in overseas subsidiaries acting as a drag on reported PAT.
Source: RHP p. 408-409, 722Shareholding, Syndicate & Leadership
Leadership & Skin in the Game
Leadership: Krishna Chivukula Jr. (Whole-time Director and Chief Executive Officer) / Krishna Chivukula (Chairman and Managing Director)
Litigation: Against Company: 40 tax proceedings (₹4,212.52 million) and 5 statutory/regulatory proceedings.
Auditor / RPT Flags: Emphasis of Matter regarding the restatement of April 1, 2023 balances and reclassifications. Negative CARO remarks noting the accounting software lacks audit trail functionality at the database level for direct changes, and the inventory software lacks an audit trail entirely.
Peers & Valuation
| Company | P/E | P/B | RoE | Margin |
|---|---|---|---|---|
| Jiangsu Gian Technology Co, Ltd | 148 | — | 3.1 | — |
At the ₹485 upper band, the issue is priced at 44.6x earnings — a 70% discount to the peer median of 148.0x. This is the arithmetic of the price band against the peers the filing itself lists; it is not a view on whether the offer is worth taking.
🔍 Forensic Findings — What the Footnotes Say
Findings from across the filing — the notes, MD&A, related-party disclosures, contingent liabilities, CARO and litigation, alongside the risk section itself. Each carries where it was found, so you can see which were buried and which were disclosed. Findings marked derived are computed from the filed numbers against a stated rule, shown beside them.
The company reported exceptional items of ₹780.36 million in FY26, ₹1,010.78 million in FY25, and ₹764.74 million in FY24, primarily due to impairments of goodwill, property, plant, and equipment at its acquired US and UK subsidiaries (Triax Industries and Conway Marsh).
RHP p. 321, 722, Note 32 Exceptional ItemsPromoter Krishna Chivukula appeared on the list of disqualified directors under Section 164(2)(a) from November 2016 to October 2021. Additionally, MCA issued Show Cause Notices in 2024 for failure to appoint a cost auditor for FY22, FY23, and FY24.
RHP p. 24, 382, Risk FactorsSeveral historical corporate records, including Forms 23 and 5 for increases in authorized share capital, as well as records relating to certain allotments and transfers of Equity Shares, are untraceable.
RHP p. 46, 175-176, Risk FactorsThe statutory auditor issued a negative CARO remark stating the company's accounting software lacks audit trail functionality at the database level to log direct changes, and its inventory software lacks an audit trail entirely.
RHP p. 683, Annexure VIIThe company failed to obtain consent from its registered valuers to disclose the valuation details and valuer names regarding its acquisitions of Triax Industries, Conway Marsh, and Phoenix DeVentures.
RHP p. 46, 169, Risk FactorsAgainst Company: 40 tax proceedings (₹4,212.52 million) and 5 statutory/regulatory proceedings.
RHP p. 112, 158, 208, 258, 480, 683Emphasis of Matter regarding the restatement of April 1, 2023 balances and reclassifications. Negative CARO remarks noting the accounting software lacks audit trail functionality at the database level for direct changes, and the inventory software lacks an audit trail entirely.
RHP p. 112, 158, 208, 258, 480, 683Company's Claims vs Reality
We stress-test each claim against the filing's own data.
Does the independent industry report validate this market leadership position?
RHP p. 192, 411, Our BusinessDo the financials show export dominance and diversified origins?
RHP p. 201 (Revenue from outside India was 77.20% in FY26)Proprietary SWOT — Company-Specific
Strengths
- Global market leadership with a 6.8% share in the highly specialized Metal Injection Molding (MIM) industry.
- Highly diversified customer base across automotive, defence, medical, and aerospace sectors, with the top 10 customers accounting for only 38.41% of revenue in FY26, minimizing concentration risk.
Weaknesses
- Poor M&A track record, evidenced by over ₹2,500 million in impairment write-downs on goodwill and assets for acquired overseas subsidiaries (Triax, Conway Marsh) over the last three years.
- Weak internal controls and compliance culture, highlighted by missing statutory records, historical director disqualification, and CARO remarks on deficient accounting software audit trails.
Opportunities
- Expansion into emerging adjacent technologies such as 3D printing, vacuum casting, and '2K MIM' technology.
- Rising global demand from the medical devices and industrial gas turbine (IGT) sectors offers a highly scalable OEM-focused runway.
Threats (material, not boilerplate)
- Significant contingent liabilities and tax disputes. footnotes
Why it matters: The company has ₹2,274.49 million in contingent liabilities, primarily driven by disputed Excise, Service Tax, VAT, and Income Tax demands. An adverse ruling would drain operating cash flows. - Environmental and pollution control notices. litigation
Why it matters: Received notices from the Karnataka State Pollution Control Board to retrofit or shut down DG sets. Non-compliance could halt local manufacturing operations.
Live Subscription Status
Total subscription is fed live from the exchange data feed. The category split (QIB, NII, retail) is not carried by that feed and is added by hand where it is material — so it is shown only when we have actually verified it, rather than left as blanks.
Allotment Status
Check your allotment on the registrar's portal → Registrar: MUFG Intime India
Allotment is decided by the registrar, not by us and not by the exchange. In an oversubscribed retail book, allotment is by lottery, so a large application does not improve your odds beyond one lot. If money stays blocked after the refund date, the mandate expiry (07 Sep 2026) is the date to raise with your bank.
Analyst Q&A: Burning Questions
Facts from the filing. No recommendation — that layer arrives once our Research Analyst registration is live.
Where is the money going?
The Offer comprises a Fresh Issue of ₹5,000 million and an Offer for Sale of up to 68.29 million shares. From the Fresh Issue, ₹4,000 million will be utilized to prepay/repay outstanding borrowings, with the balance for general corporate purposes.
RHP p. 101, 208How concentrated is the customer and supplier base?
Customer concentration is remarkably low; the top 10 customers accounted for only 38.41% of operating revenue in FY26. Supplier concentration is also moderate, with the top 10 suppliers accounting for 42.91% of raw material purchase costs in FY26.
RHP p. 106, 714Is it profitable and growing?
Yes. Revenue from operations grew from ₹28,703.95 million in FY24 to ₹41,929.85 million in FY26. Restated profit for the year increased concurrently from ₹2,837.34 million to ₹5,335.43 million, delivering an EBITDA margin of 25.54% and a RoE of 21.26% in FY26.
RHP p. 64, 340, 721What sits in the footnotes / contingent liabilities?
The company holds significant contingent liabilities of ₹2,274.49 million, entirely driven by disputed direct and indirect tax demands. The footnotes also reveal over ₹2,555 million in exceptional impairment charges across the last three years tied to underperforming overseas acquisitions. Finally, it has historical MCA notices for cost audit failures and missing corporate records.
RHP p. 46, 321, 326, 382, 752What Earlier Investors Paid
Early capital takes real risk and is fairly rewarded for it — a large multiple built over many years is normal. What deserves a closer look is a steep step-up in a short window: a round priced cheaply only months before the offer.
| Shareholder | Priced at | When | vs IPO price |
|---|---|---|---|
| Employees of our Company | ₹1.00 | 2026-01-23 | 485.0x |
| This round priced within the last year, yet the offer is at roughly 485.0x that price. A step-up this steep in this little time is worth understanding: what changed in the business to justify it? | |||
| Allotted below the band — 1 entries | |||
| Green Meadows Investments Ltd | ₹496.00 | 2023-06-07 | as disclosed |
The 1 allotments listed under “allotted below the band” are shown at their as-disclosed per-share price. They are not adjusted for any later bonus issue or share split, so where a company has issued bonus shares the raw multiple understates the true return and can even read as a loss when none was made. We show them as filed and decline to compute a misleading multiple.
Prices are as stated in the filing’s allotment history and are not adjusted for later bonus issues or share splits. Where a company has issued bonus shares, the multiples above understate the true return and can even read as losses. Adjusting for that is on our list; until it is done we would rather show the raw disclosure and tell you its limits than publish a confident number that is wrong.
Lock-in Expiry Calendar
Shares held before the IPO cannot be sold immediately; they unlock in tranches. When a tranche unlocks, more shares become eligible to trade. Retail investors are frequently caught unaware by these dates. The schedule below follows from the listing date; quantities are shown only where the filing discloses them.
- 30 Jan 2028Minimum Promoters' Contribution18 months
- 30 Jan 2027Promoters' shareholding in excess of 20%six months
- 30 Jan 2027Entire pre-Offer Equity Share capitalsix months
- 28 Oct 2026Anchor Investors (50%)90 days
- 29 Aug 2026Anchor Investors (50%)30 days
An unlock means more shares may be sold — not that they will be, and not that the price will move. We state the dates; what you do with them is your call.
What Changed Between the DRHP and the RHP
Companies file a draft prospectus, then a final one. The changes in between are rarely reported, and they can be revealing.
| Item | In the DRHP | In the RHP / Addendum |
|---|---|---|
| Fresh Issue Size The fresh issue size was reduced by exactly 50% between the draft and the final filing. | Up to ₹10,000.00 million | Up to ₹5,000.00 million |
| Offer for Sale (OFS) The OFS was cut by nearly 47%. The Corporate Promoter (Green Meadows Investments Ltd) halved its offered shares from 120,507,693 to 60,524,322, and Individual Selling Shareholder John Anthony Dexheimer withdrew his offering of 1,400,000 shares entirely. | Up to 129,674,393 Equity Shares | Up to 68,291,022 Equity Shares |
| Use of Proceeds (Repayment of Borrowings) Following the reduction of the fresh issue size, the allocation for the repayment or prepayment of borrowings was reduced by ₹3,200.00 million. | ₹7,200.00 million | ₹4,000.00 million |
| Financial Information Period The restated financial statements were rolled forward by one full fiscal year, adding the newly completed FY26 and dropping FY23. | Fiscals 2025, 2024 and 2023 | Fiscals 2026, 2025 and 2024 |
| Pre-Offer Equity Share Capital The pre-offer outstanding share capital increased by 2,122,300 shares due to the exercise of employee stock options between the filings. | 482,030,772 Equity Shares | 484,153,072 Equity Shares |
Educational, grounded entirely in the company's filings (DRHP/RHP). Not investment advice. FinMinutes does not provide buy/sell recommendations.
